Values as of: 2025-04-08
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 14.27Change
-1.22 (-7.88)%Market Cap
USD 2.55BVolume
3.70MVerdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| BDX | Becton Dickinson and Company |
-1.64 (-0.81%) |
USD 57.94B |
| ALC | Alcon AG |
+0.63 (+0.69%) |
USD 44.32B |
| RMD | ResMed Inc |
-2.48 (-1.16%) |
USD 31.43B |
| BAX | Baxter International Inc |
+0.02 (+0.07%) |
USD 14.28B |
| SOLV | Solventum Corp. |
-0.26 (-0.39%) |
USD 11.45B |
| AVTR | Avantor Inc |
-0.15 (-0.97%) |
USD 10.37B |
| ATR | AptarGroup Inc |
+1.06 (+0.74%) |
USD 9.51B |
| TFX | Teleflex Incorporated |
-0.30 (-0.23%) |
USD 6.39B |
| STVN | Stevanato Group SpA |
-0.56 (-2.47%) |
USD 5.98B |
| BLCO | Bausch + Lomb Corp |
-0.08 (-0.67%) |
USD 4.29B |
N/A
| Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -41.06% | 16% | F | 5% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -41.06% | 16% | F | 5% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 3.48% | 89% | A- | 83% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 3.48% | 89% | A- | 75% | C | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 0.77% | 50% | F | 38% | F | ||
| Dividend Return | 0.77% | 50% | F | 26% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 42.78% | 33% | F | 21% | F | ||
| Risk Adjusted Return | 1.80% | 44% | F | 23% | F | ||
| Market Capitalization | 2.55B | 33% | F | 70% | C- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
